Special Issue

Glioblastoma Cell: From Molecular Target to Innovative Therapy

Message from the Guest Editor

Gliomas are the most malignant and aggressive form of brain tumors and account for the majority of brain cancer-related deaths. Malignant gliomas are treated with chemo (temozolomide) and radiotherapy, with only a slight benefit in survival time. Numerous advances have been made in understanding the biology of gliomas, including the discovery of cancer stem cells, called glioma stem cells (GSCs). Several molecular markers have been proposed as predictors for the prognosis of patients with glioblastoma: some of the best-known molecular markers (IDH, EGFR, p53, PI3K, Rb, and RAF). This special issue will cover all aspects of glioblastoma cell growth. Studies on new adjuvant substances for the treatment of glioblastoma, advanced personalized molecular diagnosis, and response to novel molecular targeted therapy will be promising. Along with original research articles of in vitro and in vivo models of glioblastoma, comprehensive and up-to-date reviews of these topics are encouraged to summarize and understand the current state and future directions of glioblastoma cell biology and therapy.

Guest Editor

Dr. Antonella Arcella
I.R.C.C.S Neuromed, Via Atinense, 18, 86077 Pozzilli, IS, Italy

Deadline for manuscript submissions

closed (25 March 2022)

Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/si/78461

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/cells

Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/journal/cells

About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny
Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch
Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).